CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus.

Autor: Hybel TE; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Vase MØ; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Lauridsen KL; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Enemark MB; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Møller MB; Department of Pathology, Odense University Hospital, Odense, Denmark., Pedersen C; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark., Pedersen G; Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark., Hamilton-Dutoit S; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Obel N; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark., Schade Larsen C; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark., d'Amore F; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Ludvigsen M; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jun; Vol. 63 (6), pp. 1479-1483. Date of Electronic Publication: 2022 Jan 12.
DOI: 10.1080/10428194.2021.2023741
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje